These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23734742)

  • 1. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma.
    Ohnishi K; Komohara Y; Saito Y; Miyamoto Y; Watanabe M; Baba H; Takeya M
    Cancer Sci; 2013 Sep; 104(9):1237-44. PubMed ID: 23734742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma.
    Ohnishi K; Yamaguchi M; Erdenebaatar C; Saito F; Tashiro H; Katabuchi H; Takeya M; Komohara Y
    Cancer Sci; 2016 Jun; 107(6):846-52. PubMed ID: 26991548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis.
    Asano T; Ohnishi K; Shiota T; Motoshima T; Sugiyama Y; Yatsuda J; Kamba T; Ishizaka K; Komohara Y
    Cancer Sci; 2018 May; 109(5):1723-1730. PubMed ID: 29520898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.
    Saito Y; Ohnishi K; Miyashita A; Nakahara S; Fujiwara Y; Horlad H; Motoshima T; Fukushima S; Jinnin M; Ihn H; Takeya M; Komohara Y
    Cancer Immunol Res; 2015 Dec; 3(12):1356-63. PubMed ID: 26297710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer.
    Shiota T; Miyasato Y; Ohnishi K; Yamamoto-Ibusuki M; Yamamoto Y; Iwase H; Takeya M; Komohara Y
    PLoS One; 2016; 11(11):e0166680. PubMed ID: 27861544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer.
    Takeya H; Shiota T; Yagi T; Ohnishi K; Baba Y; Miyasato Y; Kiyozumi Y; Yoshida N; Takeya M; Baba H; Komohara Y
    Pathol Int; 2018 Dec; 68(12):685-693. PubMed ID: 30516869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD169
    Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
    Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma.
    Zhang Y; Li JQ; Jiang ZZ; Li L; Wu Y; Zheng L
    J Pathol; 2016 Jun; 239(2):231-41. PubMed ID: 27174787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of CD169
    Topf MC; Harshyne L; Tuluc M; Mardekian S; Vimawala S; Cognetti DM; Curry JM; Rodeck U; Luginbuhl A
    Otolaryngol Head Neck Surg; 2019 Jul; 161(1):67-73. PubMed ID: 30744470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses.
    Komohara Y; Ohnishi K; Takeya M
    Cancer Sci; 2017 Mar; 108(3):290-295. PubMed ID: 28002629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.
    Kawaguchi S; Kawahara K; Fujiwara Y; Ohnishi K; Pan C; Yano H; Hirosue A; Nagata M; Hirayama M; Sakata J; Nakashima H; Arita H; Yamana K; Gohara S; Nagao Y; Maeshiro M; Iwamoto A; Hirayama M; Yoshida R; Komohara Y; Nakayama H
    Cancer Immunol Immunother; 2022 Sep; 71(9):2127-2139. PubMed ID: 35044489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced number of CD169
    Strömvall K; Sundkvist K; Ljungberg B; Halin Bergström S; Bergh A
    Prostate; 2017 Nov; 77(15):1468-1477. PubMed ID: 28880401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Higher Frequency of CD14+ CD169+ Monocytes/Macrophages in Patients with Colorectal Cancer.
    Li C; Luo X; Lin Y; Tang X; Ling L; Wang L; Jiang Y
    PLoS One; 2015; 10(10):e0141817. PubMed ID: 26509874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Delivery of Antigen to Activated CD169
    Edgar LJ; Kawasaki N; Nycholat CM; Paulson JC
    Cell Chem Biol; 2019 Jan; 26(1):131-136.e4. PubMed ID: 30393066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis.
    Kong W; Wei M; Liu R; Zhang J; Wang X
    Bioengineered; 2021 Dec; 12(1):8505-8514. PubMed ID: 34607536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8
    van Dinther D; Veninga H; Iborra S; Borg EGF; Hoogterp L; Olesek K; Beijer MR; Schetters STT; Kalay H; Garcia-Vallejo JJ; Franken KL; Cham LB; Lang KS; van Kooyk Y; Sancho D; Crocker PR; den Haan JMM
    Cell Rep; 2018 Feb; 22(6):1484-1495. PubMed ID: 29425504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma growth and lymph node metastasis is independent of host CD169 expression.
    Muhsin-Sharafaldine MR; Saunderson SC; Dunn AC; McLellan AD
    Biochem Biophys Res Commun; 2017 May; 486(4):965-970. PubMed ID: 28359758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD169
    Tacconi C; Commerford CD; Dieterich LC; Schwager S; He Y; Ikenberg K; Friebel E; Becher B; Tugues S; Detmar M
    Cell Rep; 2021 Apr; 35(2):108993. PubMed ID: 33852863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals the reduction of CD169
    Maeshima Y; Kataoka TR; Vandenbon A; Hirata M; Takeuchi Y; Suzuki Y; Fukui Y; Kawashima M; Takada M; Ibi Y; Haga H; Morita S; Toi M; Kawaoka S; Kawaguchi K
    EBioMedicine; 2024 Sep; 107():105271. PubMed ID: 39173531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and functional heterogeneity of CD169⁺ and CD163⁺ macrophages from porcine lymph nodes and spleen.
    Alvarez B; Martínez P; Yuste M; Poderoso T; Alonso F; Domínguez J; Ezquerra A; Revilla C
    Dev Comp Immunol; 2014 May; 44(1):44-9. PubMed ID: 24291017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.